- Home
- WLYB vs EWTX Comparison
WLYB vs EWTX Comparison
Compare WLYB & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- EWTX
- Stock Information
- Founded
- WLYB 1807
- EWTX 2017
- Country
- WLYB United States
- EWTX United States
- Employees
- WLYB N/A
- EWTX N/A
- Industry
- WLYB Books
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- WLYB Consumer Discretionary
- EWTX Health Care
- Exchange
- WLYB Nasdaq
- EWTX Nasdaq
- Market Cap
- WLYB 2.7B
- EWTX 2.7B
- IPO Year
- WLYB N/A
- EWTX 2021
- Fundamental
- Price
- WLYB $45.38
- EWTX $31.25
- Analyst Decision
- WLYB
- EWTX Buy
- Analyst Count
- WLYB 0
- EWTX 6
- Target Price
- WLYB N/A
- EWTX $44.83
- AVG Volume (30 Days)
- WLYB 151.0
- EWTX 762.1K
- Earning Date
- WLYB 12-05-2024
- EWTX 11-07-2024
- Dividend Yield
- WLYB 3.08%
- EWTX N/A
- EPS Growth
- WLYB N/A
- EWTX N/A
- EPS
- WLYB N/A
- EWTX N/A
- Revenue
- WLYB $1,759,570,000.00
- EWTX N/A
- Revenue This Year
- WLYB N/A
- EWTX N/A
- Revenue Next Year
- WLYB $1.12
- EWTX N/A
- P/E Ratio
- WLYB N/A
- EWTX N/A
- Revenue Growth
- WLYB N/A
- EWTX N/A
- 52 Week Low
- WLYB $30.64
- EWTX $8.00
- 52 Week High
- WLYB $52.90
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- WLYB 24.20
- EWTX 46.80
- Support Level
- WLYB $49.30
- EWTX $27.00
- Resistance Level
- WLYB $52.29
- EWTX $35.50
- Average True Range (ATR)
- WLYB 0.13
- EWTX 2.36
- MACD
- WLYB -0.46
- EWTX -0.10
- Stochastic Oscillator
- WLYB 1.15
- EWTX 38.94
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is a provider of academic journals, books, pre- and post-hire assessments and training, test preparation materials, and online education program management solutions. The company's reportable segments are; Research, Learning, Held for Sale or Sold. The majority of the company's revenue is generated from the Research segment which provides peer-reviewed scientific, technical, and medical (STM) publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. Geographically, it derives maximum revenue from the United States and the rest from the United Kingdom, China, Japan, Canada, and other countries.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.